A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

Fenge Li; Liping Wang; Yixiang Zhang; Weihong Feng; Tao Ju; Zaiping Liu; Zhenglu Wang; Xueming Du

doi:10.3389/fonc.2021.640131

A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy

Front Oncol. 2021 May 31:11:640131. doi: 10.3389/fonc.2021.640131. eCollection 2021.

Authors

Fenge Li^{1

2}, Liping Wang³, Yixiang Zhang⁴, Weihong Feng¹, Tao Ju¹, Zaiping Liu⁵, Zhenglu Wang⁶, Xueming Du¹

Affiliations

¹ Department of Oncology, Tianjin Beichen Hospital, Tianjin, China.
² Department of Melanoma Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.
³ Department of Oncology, Weifang People's Hospital, Weifang, China.
⁴ Pulmonary Medicine, Weifang People's Hospital, Weifang, China.
⁵ Department of Pathology and Laboratory Medicine, IWK Women's and Children's Health Center, Halifax, NS, Canada.
⁶ Pathology Department, Tianjin First Central Hospital, Tianjin, China.

Abstract

Background: Patients with progressive thoracic malignancy characterized by large irregular tumors with necrosis and life-threatening symptoms lack effective treatments. We set out to develop a single needle cone puncture method for the Iodine-125 seed (SNCP-¹²⁵I) brachytherapy, and aim to report the initial results.

Methods: 294 patients with advanced thoracic malignancy were treated with local SNCP-¹²⁵I brachytherapy between March 2009 and July 2020, followed by thorough evaluation of clinical outcome, overall survival (OS), progression-free survival (PFS) and procedure-related complications after treatment.

Results: The overall response rate (ORR) among the treated patients was 81.0% (238/294). Life-threatening symptoms due to tumor oppression, hemoptysis and large irregular tumor with necrosis were successfully alleviated after the SNCP-¹²⁵I treatment with a remission rate at 91% to 94%. The median OS and PFS were 13.6 months and 5.8 months, respectively. Procedure-related side effects including pneumothorax (32/294), blood-stained sputum (8/294), subcutaneous emphysema (10/294), puncture site bleeding (16/294) and chest pain (6/294) were observed. Patients who were able to follow with chemotherapy or immunotherapy experienced extended OS and PFS, as compared with patients who opted to receive hospice care (16.5 months Vs. 11.2 months). Further pathological and immunological analysis showed that SNCP-¹²⁵I induced tumor lymphocytes infiltration and long-term tumor necrosis.

Conclusion: SNCP-¹²⁵I brachytherapy effectively eliminates life-threatening symptoms due to local tumor oppression, hemoptysis and large irregular and necrotic tumors in patients with unresectable chest malignancy and significantly induces local tumor regression. SNCP-¹²⁵I brachytherapy combines with chemotherapy significantly prolong OS and PFS compare with SNCP-¹²⁵I brachytherapy alone.

Keywords: life-threatening symptom; radioactive iodine-125 brachytherapy; single needle cone puncture; survival; thoracic malignancy.